iBio, Inc.
IBIO- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001420720
No open-market purchases or sales by iBio, Inc. insiders were filed in the last 90 days; 61 institutions reported holding it in 13F filings for Q3 2026, worth $44.3M in total; no superinvestor holds it.
Key figures
- Market capClose on Nov 20, 2026
- $56.4M
- Insider buysOpen market, last 90 days
- 0
- Insider sellsOpen market, last 90 days
- 0
- 13F holdersQ3 2026, +7 vs. previous quarter
- 61
- 13F valueReported value at the end of Q3 2026
- $44.3M
- Superinvestors holdingAt the end of Q3 2026
- 0
Price chart
Financials
See financial statementsFrom SEC filings, in USD.
- Revenue, FY2026
- $100.0K
- −75.0% year over year
- Net income, FY2026
- -$33.0M
- No comparable prior period
- Free cash flow, FY2026
- -$23.8M
- No comparable prior period
- Revenue, Q1 FY2027
- $1.07M
- +975.0% year over year
Revenue flow, FY2026
Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue.
Net loss for FY2026: $33.0M (33044.0% of revenue).
Short interest
See short dataFrom FINRA, settlement date Oct 30, 2026.
- Short interest
- 4.03M
- Shares sold short
- Change
- +300.4K
- +8.1% vs. previous
- Days to cover
- 7.15
- At average daily volume
Superinvestors holding IBIO, Q3 2026
Go to the superinvestors tabNo superinvestor reported holding IBIO at the end of Q3 2026.
Latest insider trades
See all insider tradesOpen-market purchases and sales by iBio, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Mar 27, 2026 (view filing) | Mar 26 | 1 day | Banjak MarcChief Legal Officer | PPurchase | +13.9K | $1.65 | +$23.0K | +125.9%25.0K after | 2 lots |
| Mar 23, 2026 (view filing) | Mar 19 | 4 days | Duran FelipeChief Financial Officer | PPurchase | +24.8K | $2.02 | +$50.2K | +223.0%36.0K after | |
| Mar 23, 2026 (view filing) | Mar 19 | 4 days | Brenner MartinSee Remarks | PPurchase | +12.3K | $2.02 | +$24.9K | +67.4%30.7K after | |
| Jan 13, 2025 (view filing) | Jan 10 | 3 days | Duran FelipeChief Financial Officer | PPurchase | +9.19K | $2.72 | +$25.0K | +471.8%11.1K after | |
| Jan 13, 2025 (view filing) | Jan 10 | 3 days | Brenner MartinSee Remarks | PPurchase | +9.19K | $2.72 | +$25.0K | +100.7%18.3K after | |
| Jan 13, 2025 (view filing) | Jan 10 | 3 days | Banjak MarcChief Legal Officer | PPurchase | +9.19K | $2.72 | +$25.0K | +490.2%11.1K after | |
| Jan 13, 2025 (view filing) | Jan 10 | 3 days | Arkowitz DavidDirector | PPurchase | +18.4K | $2.72 | +$50.0K | New position18.4K after | |
| Jan 13, 2025 (view filing) | Jan 10 | 3 days | Clark William DDirector | PPurchase | +1.84K | $2.72 | +$5.00K | New position1.84K after | |
| Jan 13, 2025 (view filing) | Jan 10 | 3 days | Parada Antonio Bernardino GuimaraesDirector | PPurchase | +183.8K | $2.72 | +$500.0K | New position183.8K after | |
| Jan 13, 2025 (view filing) | Jan 10 | 3 days | Sender GaryDirector | PPurchase | +9.19K | $2.72 | +$25.0K | New position9.19K after |
Top 10 13F holders, Q3 2026
See all 61 holdersThe largest institutional positions in iBio, Inc. at the end of Q3 2026; share changes are against Q2 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Silverarc Capital Management, LLC | 5,357,088 | $6.32M | 0.77% | +1,836,598+52.2% | Added |
| Affinity Asset Advisors, LLC | 4,130,427 | $4.87M | 0.28% | +122,546+3.1% | Added |
| Cormorant Asset Management, LP | 3,570,000 | $4.21M | 0.28% | 00.0% | Unchanged |
| Vestal Point Capital, LP | 2,600,000 | $3.07M | 0.08% | 00.0% | Unchanged |
| Woodline Partners LP | 2,238,450 | $2.64M | 0.01% | +461,903+26.0% | Added |
| Vanguard Capital Management LLC | 2,098,151 | $2.48M | 0.00% | 00.0% | Unchanged |
| Frazier Life Sciences Management, L.P. | 1,953,467 | $2.31M | 0.06% | 00.0% | Unchanged |
| Balyasny Asset Management LLC | 1,592,008 | $1.88M | 0.00% | +421,115+36.0% | Added |
| Ensign Peak Advisors, Inc | 1,565,758 | $1.85M | 0.00% | −266,699−14.6% | Reduced |
| Bank of America Corp | 1,488,537 | $1.76M | 0.00% | +367,045+32.7% | Added |
Holders of 5% or more of IBIO
See all 10 holders and filingsHolders whose latest Schedule 13D or 13G filing reports 5% or more of iBio, Inc..
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| Cormorant Asset Management, LP | 13G/A | 9.99%5.12M shares | 0.00 ppfrom 9.99% | Nov 14, 20253 filings | Aug 14, 2026 | SEC |
| Affinity Asset Advisors, LLC | 13G/A | 9.99%5.07M shares | 0.00 ppfrom 9.99% | Aug 26, 20255 filings | Aug 13, 2026 | SEC |
| Silverarc Capital Management, LLC | 13G | 9.99%2.18M shares | New | Nov 14, 20251 filing | Nov 14, 2025 | SEC |
| Adage Capital Management, L.P. | 13G | 9.99%2.18M shares | New | Nov 13, 20251 filing | Nov 13, 2025 | SEC |
| Sirenia Capital Management LP | 13G | 9.90%11.6M shares | New | May 15, 20261 filing | May 15, 2026 | SEC |